Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...
Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...
Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults
The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...
Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia
Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in...
CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars
The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...
CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure
The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...
BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...
Innovent Biologics Denies Lab Closure, Confirms Relocation to California
Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...
BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift
The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...
European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...
Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...
Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development
Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...
Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...
BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery
BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou...
Sichuan Biokin Gains NMPA Approval for Phase I Study of BL-M05D1 in Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has received approval from the National Medical Products...
Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication
Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA)...
Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish...
Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment
Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering...
Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial
Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug...